{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:23:26Z","timestamp":1775856206580,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T00:00:00Z","timestamp":1317686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p><jats:bold>Summary\u2002<\/jats:bold> Alternative treatments for seborrhoeic dermatitis are needed because of the increasing risk of anti\u2010fungal resistance to existing therapies. To investigate the efficacy, safety and tolerability of topical scalp treatment with K301 solution. Two multi\u2010centre, randomised, double\u2010blind studies were conducted. Study I: 4\u2003weeks of once\u2010daily treatment with either one form of K301 (a or b) or placebo, followed by 4\u2003weeks of maintenance treatment three times\u2010per\u2010week. Study II: 4\u2003weeks of K301 (a) or placebo once\u2010daily. Study I: 98 patients enrolled (K301a\u2003+\u2003b, <jats:italic>n<\/jats:italic>\u2003=\u200351; placebo, <jats:italic>n<\/jats:italic>\u2003=\u200347) and 83 completed; 201\u2003entered Study II (K301a, <jats:italic>n<\/jats:italic>\u2003=\u2003136; placebo, <jats:italic>n<\/jats:italic>\u2003=\u200365) and 195\u2003completed. Erythema and desquamation sum score at 4\u2003weeks, mean (SD) values were 2.4\u2003(2.0) for K301a<jats:italic>\u2003<\/jats:italic>+\u2003b and 3.2\u2003(2.2) for placebo in Study I (<jats:italic>P<\/jats:italic>\u2003=\u20030.025) and 2.5\u2003(1.9) for K301a and 3.2\u2003(1.8) for placebo in Study II (not significant). In both studies, 4\u2010week desquamation scores were significantly improved for K301 vs. placebo (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Both studies showed significant improvements in symptomatic investigator and patient assessments for K301 over placebo after 4\u2003weeks (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Treatment\u2010related adverse events were generally mild and included some smarting or burning upon application. The K301 was well tolerated and associated with clinically meaningful improvements in seborrhoeic dermatitis endpoints.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2011.02126.x","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T08:26:04Z","timestamp":1317716764000},"page":"393-403","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double\u2010blind, randomised, placebo\u2010controlled studies"],"prefix":"10.1111","volume":"55","author":[{"given":"Lennart","family":"Emtestam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5ke","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell","family":"Rensfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,4]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1984.tb04050.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1984.tb06631.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00693.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1461-1244.2004.02409.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1461-1244.2004.02382.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1461-1244.2004.02381.x"},{"key":"e_1_2_8_8_2","first-page":"1001","article-title":"A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions","volume":"6","author":"Elewski BE","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.034"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2005.10119.x"},{"issue":"1","key":"e_1_2_8_11_2","first-page":"119","article-title":"Antifungal drug resistance in pathogenic fungi","volume":"36","author":"Vanden Bossche H","year":"1998","journal-title":"Med Mycol"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074118"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1971.tb06871.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2340\/0001555517778","article-title":"Urea in the treatment of dry skin","volume":"177","author":"Swanbeck G","year":"1992","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.1978.17.9.703"},{"key":"e_1_2_8_16_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2340\/0001555571148150","article-title":"Antibacterial and antifungal properties of propylene glycol, hexylene glycol, and 1,3\u2013butylene glycol in vitro","volume":"71","author":"Kinnunen T","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2340\/00015555609293","article-title":"Propylene glycol in the treatment of tinea versicolor","volume":"60","author":"Faergemann J","year":"1980","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_8_19_2","first-page":"69","article-title":"Propylene glycol in the treatment of seborrheic dermatitis of the scalp, a double\u2013blind study","volume":"42","author":"Faergemann J","year":"1988","journal-title":"Cutis"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/16537150601092944"},{"key":"e_1_2_8_21_2","unstructured":"European Medicines Agency.ICH Topic E9: Statistical Principles for Clinical Trials. CPMP\/ICH\/363\/96. September 1998."},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.007"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb08680.x"},{"key":"e_1_2_8_24_2","first-page":"646","article-title":"Efficacy and safety of a new once\u2010daily ketoconazole 2% gel in the treatment of seborrhoeic dermatitis: a phase III trial","volume":"5","author":"Elewski B","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.1.47"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2011.02126.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2011.02126.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:59:47Z","timestamp":1698670787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2011.02126.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,4]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1439-0507.2011.02126.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02126.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,4]]}}}